{"id":740603,"date":"2023-03-16T07:06:48","date_gmt":"2023-03-16T11:06:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/"},"modified":"2023-03-16T07:06:48","modified_gmt":"2023-03-16T11:06:48","slug":"ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/","title":{"rendered":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>AC Immune<\/strong><br \/>\n        <strong>Reports Full Year 2022 Financial Results and Provides Corporate Update<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023<\/li>\n<li style=\"text-align:justify\">ACI-24.060 anti-amyloid-beta vaccine for Alzheimer\u2019s disease (AD) showed positive initial safety and immunogenicity in Phase 1b\/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024<\/li>\n<li style=\"text-align:justify\">ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment<\/li>\n<li style=\"text-align:justify\">2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million providing runway into Q3 2024, excluding potential milestone payments<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Lausanne, Switzerland,<\/strong><br \/>\n        <strong>March<\/strong><br \/>\n        <strong>16<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong>202<\/strong><br \/>\n        <strong>3<\/strong> \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the year ended December 31, 2022, and provided a corporate update.<\/p>\n<p align=\"justify\">\n        <strong>Dr.\u00a0Andrea Pfeifer, CEO\u00a0of<\/strong>\u00a0<strong>AC Immune SA, commented:<\/strong> \u201cThanks to the strong progress by our experienced team over the past year, we now have highly innovative vaccines targeting neurotoxic species of Abeta, Tau or a-syn in mid- to late-stage development for Alzheimer\u2019s and Parkinson\u2019s disease, respectively. This progress was highlighted by ABATE\u2019s successful interim readout in AD, which is enabling the quick and informed transition to this adaptive trial\u2019s next cohorts. Importantly, ABATE remains on track for additional readouts on ACI-24.060\u2019s safety and immunogenicity this year, and for interim Abeta PET analyses in 2024 that will provide an opportunity for early de-risking and potentially a rapid transition to a pivotal program.\u201d<\/p>\n<p align=\"justify\">\u201cTogether, our vaccines and the highly specific diagnostics we are developing against targets such as Tau and a-syn form the cornerstone of our strategy to enable precision medicine for neurodegenerative diseases. With this strategy, our long-term goal is to identify and treat the multifactorial pathologies of each patient at their earliest stages, so that we can minimize irreversible neuronal damage and enable disease prevention.\u201d<\/p>\n<p align=\"justify\">\n        <strong>2022 and Subsequent Highlights<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Pipeline Progress<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Vaccine<\/strong><br \/>\n        <strong> Programs<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-aci-24060-anti-amyloid-beta-vaccine-alzheimers-shows\" rel=\"nofollow noopener\" target=\"_blank\">P<\/a><br \/>\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-aci-24060-anti-amyloid-beta-vaccine-alzheimers-shows\" rel=\"nofollow noopener\" target=\"_blank\">ositive initial interim safety and immunogenicity data<\/a> from the first AD cohort of the Phase 1b\/2 ABATE trial of ACI-24.060, AC Immune\u2019s wholly-owned anti-amyloid beta (Abeta) SupraAntigen\u00ae vaccine candidate. Based on these data, ABATE has been expanded, as planned, to begin screening of individuals with Down syndrome (DS) for participation in part 2 of the trial and also to evaluate higher doses in patients with AD. Interim safety and immunogenicity data from AD and DS cohorts are expected in the second half of 2023.<\/li>\n<li style=\"text-align:justify\">ACI-35.030, a potential first-in-class anti-pTau vaccine candidate, was <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-alzheimers-disease-vaccine-candidate-aci-35030\" rel=\"nofollow noopener\" target=\"_blank\">selected for further development<\/a>, based on clinical data from a Phase 1b\/2 trial in AD presented at CTAD 2022. These data showed that vaccination with ACI-35.030 was well tolerated and elicited a strong, durable, and boost-able antibody response against pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments. ACI-35.030, generated using AC Immune\u2019s SupraAntigen\u00ae technology platform, is being developed in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson.<\/li>\n<li style=\"text-align:justify\">ACI-24.060 <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-aci-24-data-brain-communications-show-abeta-vaccine\" rel=\"nofollow noopener\" target=\"_blank\">p<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-aci-24-data-brain-communications-show-abeta-vaccine\" rel=\"nofollow noopener\" target=\"_blank\">reclinical data<\/a> published in the peer-reviewed journal <a href=\"https:\/\/academic.oup.com\/braincomms\/article-lookup\/doi\/10.1093\/braincomms\/fcac022\" rel=\"nofollow noopener\" target=\"_blank\"><em>Brain Communications<\/em><\/a>, showed it was well tolerated and generated a broad polyclonal immune response with high titers of antibodies against neurotoxic pyroglutamate Abeta (pyroGlu-Abeta), a major component of Abeta plaques. Additional preclinical data demonstrated ACI-24.060\u2019s strong immunogenicity against another key neurotoxic Abeta species, oligomeric Abeta.<\/li>\n<li style=\"text-align:justify\">A\u00a0<a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-anti-abeta-vaccine-results-phase-1b-study-down\" rel=\"nofollow noopener\" target=\"_blank\">peer-reviewed publication<\/a> in\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35532913\/\" rel=\"nofollow noopener\" target=\"_blank\"><em>JAMA Neurology<\/em><\/a> showed that the first generation formulation of ACI-24.060 was safe and elicited an immune response in the first-ever clinical study of an anti-Abeta vaccine in individuals with DS. Data from the Phase 1b study also provided evidence of target engagement by the polyclonal response to the studied vaccine.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Antibody Programs<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/detailed-data-phase-ii-crenezumab-alzheimers-prevention\" rel=\"nofollow noopener\" target=\"_blank\">Detailed results<\/a> from the Phase 2 Alzheimer\u2019s Prevention Initiative (API) study evaluating the anti-Abeta monoclonal antibody crenezumab in autosomal dominant Alzheimer\u2019s disease (ADAD) were presented at the 2022 Alzheimer\u2019s Association International Conference (AAIC) by AC Immune\u2019s partner Genentech, a member of the Roche group, and the Banner Alzheimer\u2019s Institute. Numerical differences favoring crenezumab were observed across both co-primary endpoints, as well as multiple secondary and exploratory endpoints, though none were statistically significant. All participants in the study were offered up to one year of continued treatment (crenezumab for all carriers and placebo for all non-carrier) following the end of the double-blind period while primary results and additional analyses were pending. Final efficacy visits have begun.<\/li>\n<li style=\"text-align:justify\">Further biofluid biomarker data from the Phase 2 Lauriet trial of the anti-Tau antibody semorinemab in mild-to-moderate AD were presented in a poster at CTAD 2022. Results featured in the poster showed statistically significant post-treatment reductions in pTau and total Tau in the cerebrospinal fluid with semorinemab versus placebo, supporting target engagement and modulation in the central nervous system. The Lauriet open label extension study is ongoing.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Diagnostic Programs<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">The <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-first-live-images-alpha-synuclein-human-brain\" rel=\"nofollow noopener\" target=\"_blank\">first live images <\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-first-live-images-alpha-synuclein-human-brain\" rel=\"nofollow noopener\" target=\"_blank\">of a-syn i<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-first-live-images-alpha-synuclein-human-brain\" rel=\"nofollow noopener\" target=\"_blank\">n human brains<\/a> were shown using ACI-12589, an a-syn PET tracer discovered using AC Immune\u2019s Morphomer\u00ae platform. Analyses from a clinical study of the tracer presented at AD\/PD\u2122 2022 showed enhanced contrast and a-syn target specificity in patients with multiple system atrophy (MSA), as well as increased tracer retention in brain areas affected by MSA disease processes, highlighting ACI-12589\u2019s potential as the first non-invasive diagnostic for alpha-synucleinopathies (e.g. MSA).<\/li>\n<li style=\"text-align:justify\">AC Immune\u2019s partner, Life Molecular Imaging, <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-partner-life-molecular-imaging-initiates-phase-3-study\" rel=\"nofollow noopener\" target=\"_blank\">imaged the first patient<\/a> in the pivotal Phase 3 <strong>ADvance<\/strong> trial evaluating the Tau PET tracer, PI-2620, in AD. PI-2620 was discovered and developed using the Morphomer\u00ae platform as part of a research collaboration between AC Immune and LMI.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Management Team<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Expanded executive team with the appointment of <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-changes-senior-management\" rel=\"nofollow noopener\" target=\"_blank\">Howard Donovan<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-changes-senior-management\" rel=\"nofollow noopener\" target=\"_blank\">as Chief HR Officer<\/a>. Prior to joining AC Immune, Mr. Donovan led People Services at the World Economic Forum.<\/li>\n<li style=\"text-align:justify\">Promoted Christopher Roberts to <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-changes-senior-management\" rel=\"nofollow noopener\" target=\"_blank\">Interim Chief Financial Officer and <\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-changes-senior-management\" rel=\"nofollow noopener\" target=\"_blank\">Vice President, Finance<\/a>. Mr. Roberts previously held the title of Associate Vice President, Finance, and prior to joining AC Immune worked as a Senior Manager for Ernst and Young.<\/li>\n<li style=\"text-align:justify\">Promoted <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-changes-senior-management\" rel=\"nofollow noopener\" target=\"_blank\">Julian Snow to Vice President, U.S. Finance &amp; Corporate Development<\/a>. Mr. Snow previously held the title of Associate Vice President, Financial Reporting and prior to joining AC Immune worked as a manager at BDO.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Thought Leadership and Collaborations<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Received a <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-grant-michael-j-fox-foundation-continued\" rel=\"nofollow noopener\" target=\"_blank\">follow-on <\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-grant-michael-j-fox-foundation-continued\" rel=\"nofollow noopener\" target=\"_blank\">grant<\/a> from The Michael J. Fox Foundation\u00a0for Parkinson\u2019s Research (MJFF) to support enhanced clinical studies of ACI-12589.<\/li>\n<li style=\"text-align:justify\">Received <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-awarded-new-grants-mjff-and-target-als-supporting\" rel=\"nofollow noopener\" target=\"_blank\">new grants<\/a> from MJFF and the Target ALS Foundation\u00a0that collectively provide more than USD 500,000 in additional non-dilutive capital to support the advancement of diagnostic programs targeting TDP-43 (TAR DNA-binding protein 43).<\/li>\n<li style=\"text-align:justify\">AC Immune Co-Founder and CEO Dr.\u00a0Andrea Pfeifer <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-ceo-andrea-pfeifer-receives-aenne-burda-award\" rel=\"nofollow noopener\" target=\"_blank\">received the prestigious\u00a0<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-ceo-andrea-pfeifer-receives-aenne-burda-award\" rel=\"nofollow noopener\" target=\"_blank\">Aenne<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-ceo-andrea-pfeifer-receives-aenne-burda-award\" rel=\"nofollow noopener\" target=\"_blank\">Burda<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-ceo-andrea-pfeifer-receives-aenne-burda-award\" rel=\"nofollow noopener\" target=\"_blank\">\u00a0Award for Creative Leadership<\/a>\u00a0in recognition of her work in the field of neurodegenerative diseases.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Key <\/strong><br \/>\n        <strong>Achieved and Anticipated 2023 Milestones<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">ACI-24.060<br \/>anti-Abeta vaccine<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Reported interim Phase 1b safety and immunogenicity data from first AD cohort of Phase 1b\/2 ABATE study<\/li>\n<li style=\"text-align:left\">Initiation of first DS cohort of ABATE study expected in H1 2023<\/li>\n<li style=\"text-align:left\">Submission of an Investigational New Drug (IND) application to enable expansion of ABATE study to the U.S. expected in H1 2023<\/li>\n<li style=\"text-align:left\">Additional interim safety and immunogenicity data from AD cohort of ABATE study expected in H2 2023<\/li>\n<li style=\"text-align:left\">Interim safety and immunogenicity data from DS cohort of ABATE study expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">ACI-7104 <br \/>anti-a-syn vaccine<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Update from Phase 2 VACSYN study expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">ACI-35.030 <br \/>anti-pTau vaccine<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Initiation of next trial in AD expected in H2 2023 (to be followed by milestone payment)<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">Semorinemab <br \/>anti-Tau antibody<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Results from the open-label extension of the Phase 2 Lauriet trial in mild-to-moderate AD expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">Anti-TDP-43 antibody<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Advancement of candidate into preclinical development (tox) expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">a-syn-PET tracer<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Declaration of next clinical candidate for development in Parkinson\u2019s disease expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">TDP-43-PET tracer<\/td>\n<td style=\"width:443.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Clinical candidate declaration expected in H1 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Analysis of Financial Statements for the Year Ended December 31, 2022<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Cash Position: <\/strong>The Company had a total cash balance of CHF 122.6 million, composed of CHF 31.6 million in cash and cash equivalents and CHF 91.0 million in short-term financial assets. This compares to a total cash balance of CHF 198.2 million as of December 31, 2021. The Company\u2019s cash balance provides sufficient capital resources to progress into at least Q3 2024 without consideration of potential income milestone payments.<\/li>\n<li style=\"text-align:justify\">\n          <strong>Contract Revenues: <\/strong>The Company recorded CHF 3.9 million in contract revenues for the year end December 31, 2022 compared with no contract revenues in the prior year. The increase relates to the progression of PI-2620 into Phase 3 development in AD.<\/li>\n<li style=\"text-align:justify\">\n          <strong>R&amp;D Expenditures: <\/strong>R&amp;D expenses decreased by CHF 1.9 million for the year ended December 31, 2022 to CHF 60.3 million, predominantly due to:  <\/p>\n<ul type=\"circle\">\n<li style=\"text-align:justify\"><strong>Discovery and preclinical expenses (- CHF 3.<\/strong><strong>1<\/strong><strong> million): <\/strong>The Company decreased expenditures across a variety of its discovery and preclinical programs. This decrease was predominantly due to the advancement of the Company\u2019s ACI-24.060 vaccine into clinical studies.<\/li>\n<li style=\"text-align:justify\"><strong>Clinical expenses (- CHF 1.8 million): <\/strong>The Company had a net decrease in clinical expenditures largely due to the timing of activities across various cohorts and the completion of certain R&amp;D cost sharing activities for our ACI-35.030 vaccine. We increased expenditures in other clinical programs, notably for the clinical development of ACI-7104.056 and the initiation of our Phase 1b\/2a ABATE study for ACI-24.060.<\/li>\n<li style=\"text-align:justify\"><strong>Salary- and benefit-related costs (+ CHF 1.<\/strong><strong>2<\/strong><strong> million): <\/strong>Personnel expenses increased due to the net increase in FTEs in 2022 along with the annualization of 2021 hires.<\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>G&amp;A Expenditures: <\/strong>G&amp;A expenses decreased by CHF 2.1 million for the year ended December 31, 2022 to CHF 15.8 million. This decrease is related to prior year transaction costs incurred to complete the asset acquisition of Affiris\u2019 a-syn portfolio and the reduction in personnel expenses.<\/li>\n<li style=\"text-align:justify\">\n          <strong>Other Operating Income: <\/strong>The Company recorded CHF 1.3 million in grant income for R&amp;D activities performed under our grants for the year ended December 31, 2022, an increase of CHF 0.1 million compared to the prior period.<\/li>\n<li style=\"text-align:justify\">\n          <strong>IFRS Loss for the Period: <\/strong>The Company reported a net loss after taxes of CHF 70.8 million for the year ended December 31, 2022, compared with a net loss of CHF 73.0 million for the prior period. <\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>2023 Financial Guidance<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">AC Immune anticipates that its total cash burn will be in the range of CHF 65 to CHF 75 million for the full year 2023. The Company defines cash burn as operating expenditures adjusted to include capital expenditures and offset by significant non-cash items (including share-based compensation and depreciation expense).\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About AC Immune SA <\/strong><br \/>\n        <br \/>AC Immune SA\u00a0is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen<sup>\u00ae<\/sup>\u00a0and Morphomer<sup>\u00ae<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including\u00a0Genentech, a member of the Roche Group, Eli Lilly and Company, and\u00a0others, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$3\u00a0billion\u00a0in potential milestone payments.<\/p>\n<p align=\"justify\">SupraAntigen\u00ae\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in the following territories: AU, EU, CH, GB, JP, RU, SG and\u00a0USA. Morphomer\u00ae is a registered trademark of\u00a0AC Immune SA\u00a0in CN, CH, GB, JP, KR, NO and RU.<\/p>\n<p align=\"justify\">The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:450pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Head of <\/strong><br \/>\n            <strong>Investor Relations<\/strong><br \/>\n            <strong> &amp; Corporate Communications<\/strong><br \/>\n            <br \/>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email: <a href=\"mailto:gary.waanders@acimmune.com\" rel=\"nofollow noopener\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>U.S. Investors<\/strong><br \/>\n            <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>Phone: +1 212 915 2577 <br \/>Email: <a href=\"mailto:cdavis@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>International Media<\/strong><br \/>\n            <br \/>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email: <a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow noopener\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward looking statements<\/strong><br \/>\n        <br \/>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p align=\"center\">\n        <strong>Consolidated Balance Sheets<\/strong><br \/>\n        <br \/>\n        <strong>(In CHF thousands)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:102%;border-collapse:collapse\">\n<tr>\n<td style=\"width:27.05%;text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:11.22%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>As of December 31, 2022<\/strong>\n          <\/td>\n<td style=\"width:11.73%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>As of December 31, 2021<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>ASSETS<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:11.73%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Non-current assets<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:11.73%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Property, plant and equipment<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">4,259<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">5,116<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Right-of-use assets<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">2,808<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">2,914<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Intangible asset<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">50,416<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">50,416<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Long-term financial assets<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">361<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">363<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Total non-current assets<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">57,844<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">58,809<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Current assets<\/strong>\n          <\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Prepaid expenses<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,708<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,015<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Accrued income<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">408<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">975<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Other current receivables<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">392<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">428<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Short-term financial assets<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">91,000<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">116,000<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Cash and cash equivalents<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">31,586<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">82,216<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total current assets<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">128,094<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">202,634<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total assets <\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">185,938<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">261,443<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>SHAREHOLDERS\u2019 EQUITY AND LIABILITIES<\/strong>\n          <\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Share capital<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,797<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,794<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Share premium<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">431,323<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">431,251<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Treasury shares<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">(124)<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">(124)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Currency translation differences<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">10<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Accumulated losses<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">(264,015)<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">(200,942)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">168,991<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">231,979<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Long-term lease liabilities<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,253<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,340<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Net employee defined-benefit liabilities<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,213<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">7,098<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">5,466<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">9,438<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Current liabilities<\/strong>\n          <\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Trade and other payables<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">929<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,003<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Accrued expenses<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">9,417<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">16,736<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Deferred income<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">587<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">717<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">Short-term lease liabilities<\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">548<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">570<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total current liabilities<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">11,481<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">20,026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total liabilities<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">16,947<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">29,464<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.05%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total shareholders\u2019 equity and liabilities<\/strong>\n          <\/td>\n<td style=\"width:11.22%;text-align: right;vertical-align: middle;vertical-align: bottom\">185,938<\/td>\n<td style=\"width:11.73%;text-align: right;vertical-align: middle;vertical-align: bottom\">261,443<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong>Consolidated Statements of Income\/(Loss)<\/strong><br \/>\n        <br \/>(<strong>In CHF thousands, except for per<\/strong><strong>share data)<\/strong><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:27.62%;text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:22.38%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>For the Year Ended<\/strong><br \/>\n            <br \/>\n            <strong>December 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.24%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:7.59%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"width:7.55%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>2020<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Revenue<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.59%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.55%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Contract revenue<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,935<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">15,431<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total revenue<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,935<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">15,431<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Operating expenses<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Research &amp; development expenses<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(60,336)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(62,282)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(59,487)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">General &amp; administrative expenses<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(15,789)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(17,910)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(18,557)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Other operating income\/(expense), net<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,343<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,182<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,353<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Total operating expenses<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(74,782)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(79,010)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(76,691)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Operating loss<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(70,847)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(79,010)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(61,260)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Financial income<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">69<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">6,485<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">78<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Financial expense<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(355)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(581)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(184)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Exchange differences<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">393<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">113<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(555)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Finance result, net<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">107<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">6,017<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(661)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Loss before tax<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(70,740)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(72,993)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(61,921)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Income tax expense<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(13)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(3)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Loss for the period<\/strong>\n          <\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(70,753)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(72,996)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(61,921)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Loss per share:<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.62%;text-align: left;vertical-align: middle;vertical-align: top\">Basic and diluted loss for the period attributable to equity holders<\/td>\n<td style=\"width:7.24%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.85)<\/td>\n<td style=\"width:7.59%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.97)<\/td>\n<td style=\"width:7.55%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.86)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong>Consolidated Statements of Comprehensive Income\/(Loss)<\/strong><br \/>\n        <br \/>\n        <strong>(In CHF thousands)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:27.47%;text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:17.74%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>For the Year Ended<\/strong><br \/>\n            <br \/>\n            <strong>December 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:5.99%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"width:5.96%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>202<\/strong><br \/>\n            <strong>0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Loss for the period<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">(70,753)<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">(72,996)<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">(61,921)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Items that may be reclassified to income or loss in subsequent periods (net of tax):<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Currency translation differences<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">10<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Items that will not be reclassified to income or loss in subsequent periods (net of tax):<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Remeasurement gains on defined-benefit plans (net of tax)<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,426<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">956<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">726<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other comprehensive income<\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,436<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">956<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">726<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.47%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Total comprehensive loss, net of tax <\/strong>\n          <\/td>\n<td style=\"width:4.79%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.79%;text-align: right;vertical-align: middle;vertical-align: bottom\">(66,317)<\/td>\n<td style=\"width:5.99%;text-align: right;vertical-align: middle;vertical-align: bottom\">(72,040)<\/td>\n<td style=\"width:5.96%;text-align: right;vertical-align: middle;vertical-align: bottom\">(61,195)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong>Reconciliation of loss to adjusted loss and<\/strong><br \/>\n        <br \/>\n        <strong>loss per share to adjusted loss per <\/strong><br \/>\n        <strong>share<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:98%;border-collapse:collapse\">\n<tr>\n<td style=\"width:28.2%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:21.8%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>For the Year Ended<\/strong><br \/>\n            <br \/>\n            <strong>December 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>(In CHF thousands, except for share and per share data)<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"width:7.28%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2020<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Loss<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(70,753)<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(72,996)<\/strong>\n          <\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(61,921)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Adjustments:<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Non-cash share-based payments<sup>1<\/sup><\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,330<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,126<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,088<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Foreign currency (gains)\/losses<sup>2<\/sup><\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">(521)<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">70<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">703<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Change in fair value of derivative financial assets<sup>3<\/sup><\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">(6,459)<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Transaction costs<sup>4<\/sup><\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,144<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Adjusted loss<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(67,944)<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(74,115)<\/strong>\n          <\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(57,130)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Loss per share \u2013 basic and diluted<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.85)<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.97)<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.86)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Adjustment to loss per share \u2013 basic and diluted<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">0.04<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.02)<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">0.07<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Adjusted <\/strong><br \/>\n            <strong>l<\/strong><br \/>\n            <strong>oss per share \u2013 basic and diluted<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(0.81)<\/strong>\n          <\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(0.99)<\/strong>\n          <\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>(0.79)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.2%;text-align: left;vertical-align: middle;vertical-align: top\">Weighted-average number of shares used to compute adjusted loss per share \u2013 basic and diluted<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">83,554,412<\/td>\n<td style=\"width:7.26%;text-align: right;vertical-align: middle;vertical-align: bottom\">74,951,833<\/td>\n<td style=\"width:7.28%;text-align: right;vertical-align: middle;vertical-align: bottom\">71,900,212<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <sup>1<\/sup>Reflects non-cash expenses associated with share-based compensation for equity awards issued to directors, management and employees of the Company. This expense reflects the awards\u2019 fair value recognized for the portion of the equity award which is vesting over the period.<br \/><sup>2<\/sup>Reflects foreign currency re-measurement gains and losses for the period, predominantly impacted by the change in the exchange rate between the U.S. Dollar and the Swiss Franc.<br \/><sup>3<\/sup>Reflects the change in the fair value of the derivative financial instruments associated with two convertible notes sold to certain Affiris affiliated entities.<br \/><sup>4<\/sup>Reflects transaction costs associated with our asset acquisition for a portfolio of therapeutics targeting alpha-synuclein.<\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/a695553d-e2c9-4ecf-838b-25266f4e438b\" rel=\"noopener\">20230316_ACIU_2022 Annual results-FINAL <\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NGYwMDRmOTItMTg2My00N2I0LThkNTgtYWQzOGFkMjE2NGI4LTEwMzc0NDM=\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-beta vaccine for Alzheimer\u2019s disease (AD) showed positive initial safety and immunogenicity in Phase 1b\/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024 ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment 2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740603","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-beta vaccine for Alzheimer\u2019s disease (AD) showed positive initial safety and immunogenicity in Phase 1b\/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024 ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment 2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million &hellip; Continue reading &quot;AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T11:06:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update\",\"datePublished\":\"2023-03-16T11:06:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/\"},\"wordCount\":2654,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/\",\"name\":\"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==\",\"datePublished\":\"2023-03-16T11:06:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Market Newsdesk","og_description":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-beta vaccine for Alzheimer\u2019s disease (AD) showed positive initial safety and immunogenicity in Phase 1b\/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024 ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment 2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million &hellip; Continue reading \"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-16T11:06:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update","datePublished":"2023-03-16T11:06:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/"},"wordCount":2654,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/","name":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==","datePublished":"2023-03-16T11:06:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODE5OCM0MDE1MDk2MTYjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740603"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740603\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}